Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc.
Lipocine Inc. reported first quarter 2026 results and a key clinical update. The Phase 3 trial of LPCN 1154, an oral brexanolone for postpartum depression, did not meet its primary endpoint of improving Hamilton Depression Rating Scale scores versus placebo at hour 60 in the full analysis set.
The drug was generally well tolerated with no treatment-related serious adverse events, excessive sedation, loss of consciousness, or treatment-related discontinuations. A post hoc analysis in participants with a history of psychiatric conditions showed statistically significant and clinically meaningful HAM-D improvements versus placebo, and Lipocine has applied for breakthrough therapy and fast track designations while evaluating next steps.
Financially, as of March 31, 2026, Lipocine held $24.7 million in unrestricted cash, cash equivalents and marketable investment securities. The company generated $119,397 in TLANDO royalty revenue and recorded a net loss of $3.7 million, or $(0.54) per diluted share, compared with a net loss of $1.9 million, or $(0.35) per share, a year earlier, largely driven by higher research and development spending on LPCN 1154.
Lipocine Inc. reported a larger net loss as it continued to invest in its pipeline while strengthening its balance sheet. For the three months ended March 31, 2026, total revenues were $119,397, all from TLANDO royalties, compared with $93,864 a year earlier.
The company’s net loss widened to $3.67 million from $1.86 million, driven mainly by higher research and development expense of $2.76 million versus $1.06 million as clinical programs advanced. General and administrative costs were stable at about $1.20 million.
Liquidity improved: cash and cash equivalents were $5.02 million and marketable investment securities $19.71 million, bringing total current assets to $25.24 million. During the quarter, Lipocine sold 1,314,138 shares via its at-the-market program, generating about $12.0 million in net proceeds, which helped lift stockholders’ equity to $22.83 million. Management believes existing capital resources will fund projected operating requirements through at least May 7, 2027, but it still anticipates needing additional financing over time to support development of its CNS and liver disease candidates.
Lipocine Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026 in Salt Lake City. Stockholders will elect four directors, ratify Tanner LLC as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on executive compensation.
The company also seeks approval to amend and restate its 2014 Stock and Incentive Plan, raising the annual individual award limit from 25,000 to 100,000 shares and increasing the total shares authorized for issuance under the plan from 600,000 to 1,000,000. As of the April 6, 2026 record date, 8,025,115 common shares were outstanding, and the Board unanimously recommends voting in favor of all proposals.
Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately. He had served since 2022 as Chairman, Lead Independent Director, and a member of the Board’s compensation committee.
The company stated that Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction. On April 20, 2026, the Board appointed R. Dana Ono as the new Chairman of the Board and Lead Independent Director, ensuring continuity in independent board leadership.
Lipocine Inc. director John W. Higuchi increased his stake by purchasing 40,000 shares of common stock in an open-market transaction. He paid $2.03 per share, for a total of about $81,200. After this purchase, he directly holds 203,797 Lipocine shares.
Lipocine Inc. director John W. Higuchi reported an open-market purchase of company stock. On April 6, 2026, he bought 123,000 shares of Lipocine common stock at $2.05 per share, increasing his direct ownership to 163,797 shares after the transaction.
Lipocine Inc. director and Chief Executive Officer Mahesh V. Patel reported an open-market purchase of company stock. On this date, he bought 25,000 shares of Lipocine common stock at $2.03 per share. Following this transaction, he directly owns 160,679 common shares of Lipocine.
Lipocine Inc. Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of Lipocine common stock in an open-market transaction at $2.02 per share on April 2, 2026. Following this trade, he directly owns 135,679 shares of Lipocine common stock.